Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Betta Pharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Esophageal Carcinoma

Adenocarcinoma of the Gastroesophageal Junction

Treatments

Drug: Icotinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT01855854

CH-GI-036

Details and patient eligibility

About

This study is designed to evaluate the efficacy and safety of icotinib in treating advanced carcinoma of the gastroesophageal junction and esophagus with EGFR overexpression (IHC 3+) or positive FISH, the primary endpoint is objective response rates.

Full description

Epidermal growth factor receptor (EGFR) signaling is critical for cancer cell proliferation, invasion, metastasis, and resistance to apoptosis.EGFR is overexpressed in many epithelial malignancies and therefore makes an attractive therapeutic target.This study is designed to evaluate the efficacy and safety of icotinib in treating advanced carcinoma of the gastroesophageal junction and esophagus with EGFR overexpression (IHC 3+) or positive FISH, the primary endpoint is objective response rates. Secondary endpoints include progress-free survival, overall survival, safety and so on.

Enrollment

54 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with a histologic or cytologic diagnosis of carcinoma of the gastroesophageal junction or esophagus;
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria;
Overexpression of EGFR defined by immunohistochemistry (3+) or gene amplification by fluorescence in-situ hybridisation;
Have progressed after one chemotherapy regimen;
Age 18-75 years old with performance status of 0 to 2

Exclusion criteria

Prior targeted therapy with erlotinib, gefitinib, and so on
Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).
Known severe hypersensitivity to icotinib or any of the excipients of this product.
Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.